The Supreme Court on Thursday blocked a lower court order that would have stripped mail and telehealth access to the abortion drug mifepristone, keeping the drug widely available while a lawsuit brought by Louisiana works its way through the courts. Justices Samuel Alito and Clarence Thomas each filed separate dissents, and neither pulled punches.

The decision halted a May 1 ruling from the New Orleans-based U.S. Court of Appeals for the 5th Circuit, which had reinstated a requirement that women visit a healthcare provider in person before obtaining mifepristone. That 5th Circuit order had also suspended mail distribution of the drug. By pausing it, the high court left the FDA's 2023 regulation in place, the rule that first allowed mifepristone to be prescribed via telehealth, dispensed through pharmacies, and shipped by mail.

The immediate result: nothing changes for now. But the legal and political fault lines exposed by the case are anything but settled.

Thomas invokes the Comstock Act, calls mailing pills a 'criminal enterprise'

Justice Thomas's dissent was the more combative of the two. He argued that the drugmakers who asked the Court to intervene, Danco Laboratories and GenBioPro, had no right to relief because, in his view, mailing mifepristone already violates federal law. Thomas pointed to the Comstock Act, an 1873 anti-obscenity statute that he reads as barring the mailing of abortion-related drugs.

As AP News reported, Thomas wrote that Danco and GenBioPro were seeking protection from "lost profits from their criminal enterprise." His full dissent put it bluntly:

"Applicants are not entitled to a stay of an adverse court order based on lost profits from their criminal enterprise. They cannot, in any legally relevant sense, be irreparably harmed by a court order that makes it more difficult for them to commit crimes."

That language, "criminal enterprise," "commit crimes", is not accidental. Thomas has signaled repeatedly that he believes the Comstock Act already settles the mifepristone question. He and Alito both raised the statute during oral arguments in a 2024 mifepristone case, though the full Court ultimately sidestepped the issue by dismissing that suit on standing grounds.

Alito calls the order 'remarkable' and 'unreasoned'

Justice Alito, who by default handles emergency matters arising from the 5th Circuit, filed his own dissent. He initially placed a brief hold on the lower court's ruling to give the full Court time to decide. When the majority chose to block the 5th Circuit order entirely, Alito objected in sharp terms.

"The Court's unreasoned order granting stays in this case is remarkable. What is at stake is the perpetration of a scheme to undermine our decision" overturning constitutional abortion rights.

That line, "a scheme to undermine our decision", frames the FDA's 2023 regulation as a deliberate end-run around the Court's ruling in Dobbs, the case that returned abortion policy to the states nearly four years ago. For Alito, the question is not just about drug safety or regulatory procedure. It is about whether federal agencies can functionally nullify state abortion bans by making pills available through the mail.

The majority offered no written reasoning with its order, a common practice in emergency stay decisions but one that clearly frustrated both dissenters. Fox News confirmed that Thomas dissented from the order while Alito filed a separate dissent.

Louisiana's fight: state sovereignty vs. federal drug regulation

The underlying lawsuit was brought by Louisiana, which argued that the FDA's 2023 regulation allowing telehealth prescriptions and mail delivery of mifepristone undercut the state's abortion ban and violated its sovereignty. Louisiana Attorney General Liz Murrill, a Republican, did not mince words after the Court's action.

"It's shocking that the Supreme Court would block this common-sense return to medically ethical practices and oversight. DOJ did not defend Big Pharma, which is profiting from the illegal and unethical distribution of abortion pills. We will keep fighting."

Murrill's reference to the Justice Department is notable. The Hill reported that the DOJ told the appeals court Louisiana's lawsuit "would disrupt FDA's ongoing review, and usurp FDA's scientific role, but would also threaten chaos." Yet the Trump administration did not take a position when the case reached the Supreme Court, leaving the drugmakers to argue their own case.

That silence is worth noting. The administration's decision to stay on the sidelines left Louisiana without a federal ally at the highest level, even as the state pressed a case built on concerns that conservative voters share: that federal regulators have made it possible to circumvent state abortion laws through a mailbox.

The broader tension here is one that has surfaced in other recent disputes between Republican-appointed justices and the political coalition that put them on the bench. On mifepristone, only two of six conservative justices sided with Louisiana's position.

The drugmakers celebrate, for now

GenBioPro CEO Evan Masingill issued a statement after the ruling:

"With today's Supreme Court decision, Americans' access to mifepristone remains unchanged for now. GenBioPro is continuing to serve its customers and is committed to providing our evidence-based, essential medication to all who need it."

Danco, the manufacturer of the brand-name version, pointed to the drug's long regulatory track record. "Over the years, FDA has reviewed extensive safety and effectiveness data from dozens of clinical trials and decades' worth of real-world experience in millions of patients," Danco said. "Danco also is confident that a review of all recent, reliable data by FDA will continue to show that Mifeprex is very safe and effective."

Those statements carry a confident tone, but the companies' legal exposure is far from over. The case now heads back to the 5th Circuit, where Louisiana's underlying claims about the FDA's authority and the adequacy of its safety data will be litigated on the merits. The FDA, meanwhile, is conducting its own review of mifepristone's safety protocols, a process whose timeline and scope remain unclear.

A pattern of isolation for Thomas and Alito

This is not the first time Thomas and Alito have found themselves alone on the mifepristone question. In 2024, the Supreme Court unanimously upheld access to the drug in a separate case, ruling that doctors and medical groups opposed to abortion lacked standing to sue. Newsmax noted that in an earlier phase of the current dispute, the Court blocked 5th Circuit restrictions over the dissenting votes of Alito and Thomas alone.

The pattern raises an uncomfortable question for pro-life legal strategists. The Dobbs decision was supposed to return abortion policy to the states. But if federal drug regulations allow abortion pills to flow through the mail regardless of state law, the practical effect of Dobbs is blunted. Thomas and Alito see that clearly. The rest of the Court, at least at the emergency-stay stage, has declined to act on it.

Whether that changes when the 5th Circuit rules on the merits, and whether the full Court eventually takes the case again, remains an open question. Alito has shown no hesitation in pressing his views in dissent, and Thomas has made his reading of the Comstock Act unmistakably clear.

Mifepristone is typically used as part of a two-drug combination for medication abortion. Its availability by mail has become the central legal battleground in the post-Dobbs era, precisely because it allows women in states with strict abortion laws to obtain the drug without an in-person visit. For states like Louisiana, that amounts to a federal override of democratically enacted state policy.

Just the News reported that the Court's order granted emergency requests from Danco and GenBioPro to block the appeals court ruling, keeping the status quo intact while the litigation continues. The practical effect is that mail-order mifepristone remains available nationwide, even in states that have banned or heavily restricted abortion.

Speculation about potential Supreme Court vacancies and the ideological direction of the bench adds another layer. If the composition of the Court shifts, cases like this one could produce very different outcomes. For now, though, Thomas and Alito stand as a minority of two on the most consequential abortion-access question since Dobbs.

The Court gave no reasoning. Louisiana got no relief. And the mailbox remains open. If states that passed abortion bans expected the judiciary to help enforce them, Thursday's order was a reminder that even a conservative Supreme Court may not be willing to do so, at least not yet.